PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Orbital MALT Lymphoma after Autologous Stem Cell Transplantation for Follicular Lymphoma as Relapse of Diffuse Large B-Cell Lymphoma.

Abstract We report a patient who developed orbital MALT lymphoma after autologous peripheral blood stem cell transplantation for follicular lymphoma as relapse of diffuse large B-cell lymphoma. A 54-year-old woman with systemic lymphadenopathy was diagnosed with diffuse large B-cell lymphoma by left supraclavicular lymph node biopsy, and underwent 6 courses of R-CHOP chemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone, leading to complete response. Five years later in the follow-up, an abdominal mass with abnormal uptake was found by whole-body 2-[(18)F]fluoro-2-deoxy-D-glucose positron emission tomography, and computed tomography-guided biopsy demonstrated follicular lymphoma. She underwent 4 courses of R-IDEA chemotherapy with rituximab, ifosfamide, dexamethasone, etoposide, and cytarabine, resulting in partial response, and then, underwent autologous peripheral blood stem cell transplantation with myeloablative conditioning with R-MCEC chemotherapy (rituximab, ranimustine, cyclophosphamide, etoposide, and carboplatin). She was well for the following 3 years with no treatment until the development of a right orbital mass. The excisional biopsy this time revealed MALT lymphoma. She underwent 3 courses with rituximab monotherapy and local orbital radiation at the total dose of 30 Gy. She had no relapse for the following three years. Relapse as MALT lymphoma after hematopoietic stem cell transplantation for relapsed and refractory lymphoma may not be a poor prognostic sign.
PMID
Related Publications

Peripheral T-cell lymphoma: the role of hematopoietic stem cell transplantation.

Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma.

Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study.

Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.

Orbital MALT lymphoma, abdominal hodgkin lymphoma, and systemic diffuse large B-cell lymphoma develop sequentially in one patient.

Authors

Mayor MeshTerms
Keywords
Journal Title journal of clinical and experimental hematopathology : jceh
Publication Year Start




PMID- 28331132
OWN - NLM
STAT- MEDLINE
DA  - 20170323
DCOM- 20170410
LR  - 20170410
IS  - 1880-9952 (Electronic)
IS  - 1346-4280 (Linking)
VI  - 56
IP  - 3
DP  - 2017
TI  - Orbital MALT Lymphoma after Autologous Stem Cell Transplantation for Follicular
      Lymphoma as Relapse of Diffuse Large B-Cell Lymphoma.
PG  - 170-175
LID - 10.3960/jslrt.56.170 [doi]
AB  - We report a patient who developed orbital MALT lymphoma after autologous
      peripheral blood stem cell transplantation for follicular lymphoma as relapse of 
      diffuse large B-cell lymphoma. A 54-year-old woman with systemic lymphadenopathy 
      was diagnosed with diffuse large B-cell lymphoma by left supraclavicular lymph
      node biopsy, and underwent 6 courses of R-CHOP chemotherapy with rituximab,
      cyclophosphamide, doxorubicin, vincristine, and prednisolone, leading to complete
      response. Five years later in the follow-up, an abdominal mass with abnormal
      uptake was found by whole-body 2-[18F]fluoro-2-deoxy-D-glucose positron emission 
      tomography, and computed tomography-guided biopsy demonstrated follicular
      lymphoma. She underwent 4 courses of R-IDEA chemotherapy with rituximab,
      ifosfamide, dexamethasone, etoposide, and cytarabine, resulting in partial
      response, and then, underwent autologous peripheral blood stem cell
      transplantation with myeloablative conditioning with R-MCEC chemotherapy
      (rituximab, ranimustine, cyclophosphamide, etoposide, and carboplatin). She was
      well for the following 3 years with no treatment until the development of a right
      orbital mass. The excisional biopsy this time revealed MALT lymphoma. She
      underwent 3 courses with rituximab monotherapy and local orbital radiation at the
      total dose of 30 Gy. She had no relapse for the following three years. Relapse as
      MALT lymphoma after hematopoietic stem cell transplantation for relapsed and
      refractory lymphoma may not be a poor prognostic sign.
FAU - Matsuo, Toshihiko
AU  - Matsuo T
AD  - Department of Ophthalmology, Okayama University Hospital and Okayama University
      Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences.
FAU - Tanaka, Takehiro
AU  - Tanaka T
FAU - Fujii, Nobuharu
AU  - Fujii N
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Japan
TA  - J Clin Exp Hematop
JT  - Journal of clinical and experimental hematopathology : JCEH
JID - 101141257
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Female
MH  - Hematopoietic Stem Cell Transplantation/*methods
MH  - Humans
MH  - Lymphoma, B-Cell, Marginal Zone/drug therapy/radiotherapy/*therapy
MH  - Lymphoma, Follicular/*therapy
MH  - Lymphoma, Large B-Cell, Diffuse/*pathology
MH  - Middle Aged
MH  - Orbital Neoplasms/diagnosis/*therapy
MH  - Prognosis
MH  - Recurrence
MH  - Salvage Therapy/methods
MH  - Transplantation, Autologous
EDAT- 2017/03/24 06:00
MHDA- 2017/04/11 06:00
CRDT- 2017/03/24 06:00
AID - 10.3960/jslrt.56.170 [doi]
PST - ppublish
SO  - J Clin Exp Hematop. 2017;56(3):170-175. doi: 10.3960/jslrt.56.170.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>